Subtype
Ovarian Neoplasm
CI-CAN-00001335Explore in graph →
Non-malignant747 active trials5 approved drugs94 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001335Explore in graph →
Clinical trials
3,431 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04939701 | Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1 Expression Participants | terminated | Phase 1 / Phase 2 | 16 | Astellas Pharma Global Development, Inc.INDUSTRY | 1 | Dec 11, 2024 | clinicaltrials |
| NCT02312245 | Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | completed | Phase 2 | 13 | Mayo ClinicOTHER | 1 | Dec 5, 2024 | clinicaltrials |
| NCT04826198 | Safety and Efficacy of AsiDNATM, a DNA Repair Inhibitor, Administered Intravenously in Addition to PARP Inhibitors in Patients With Relapsed Platinum Sensitive Ovarian Cancer Already Treated With PARP Inhibitors Since at Least 6 Months(REVOCAN) | terminated | Phase 1 / Phase 2 | 13 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Dec 5, 2024 | clinicaltrials |
| NCT04713514 | OSE2101 Alone or in Combination With Pembrolizumab vs BSC in Patient With Platinum-sensitive Recurrent OC(TEDOVA) | active not recruiting | Phase 2 | 180 | ARCAGY/ GINECO GROUPOTHER | 3 | Dec 2, 2024 | clinicaltrials |
| NCT05652283 | Pamiparib Combined With Surufatinib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer | active not recruiting | Phase 2 | 37 | Bai-Rong XiaOTHER | 1 | Nov 27, 2024 | clinicaltrials |
| NCT06437353 | Surufatinib Combined With Carboplatin/Paclitaxel and Surufatinib Combined With Olaparib as First-line and Maintenance Therapy for Newly Diagnosed High-risk Ovarian Cancer | recruiting | Phase 2 | 74 | Anhui Provincial Cancer HospitalOTHER | 1 | Nov 27, 2024 | clinicaltrials |
| NCT06541314 | Fluzoparib Neoadjuvant Therapy for Ovarian Cancer | unknown | Phase 2 | 48 | Qilu Hospital of Shandong UniversityOTHER | 1 | Nov 27, 2024 | clinicaltrials |
| NCT05824975 | A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08) | recruiting | Phase 1 / Phase 2 | 358 | GI Innovation, Inc.INDUSTRY | 2 | Nov 25, 2024 | clinicaltrials |
| NCT00889382 | A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors) | completed | Phase 1 / Phase 2 | 152 | Astellas Pharma IncINDUSTRY | 10 | Nov 20, 2024 | clinicaltrials |
| NCT02124421 | HOT: HIPEC in Ovarian Cancer as Initial Treatment(CRS/HIPEC) | active not recruiting | Phase 2 | 32 | Mercy Medical CenterOTHER | 1 | Nov 19, 2024 | clinicaltrials |
| NCT02953457 | Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation | completed | Phase 2 | 40 | Roswell Park Cancer InstituteOTHER | 1 | Nov 19, 2024 | clinicaltrials |
| NCT03225989 | Trial Investigating an Immunostimulatory Oncolytic Adenovirus for Cancer | completed | Phase 1 / Phase 2 | 47 | Lokon Pharma ABINDUSTRY | 1 | Nov 19, 2024 | clinicaltrials |
| NCT03761914 | Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers | completed | Phase 1 / Phase 2 | 26 | Sellas Life Sciences GroupINDUSTRY | 1 | Nov 19, 2024 | clinicaltrials |
| NCT05261490 | Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer | terminated | Phase 1 / Phase 2 | 10 | PfizerINDUSTRY | 1 | Nov 19, 2024 | clinicaltrials |
| NCT05199272 | A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies | active not recruiting | Phase 1 / Phase 2 | 141 | 23andMe, Inc.INDUSTRY | 2 | Nov 15, 2024 | clinicaltrials |
| NCT00170625 | Therapy With Topotecan and Carboplatin by Patients With Relapsed Ovarian Cancer | completed | Phase 1 / Phase 2 | 28 | North Eastern German Society of Gynaecological OncologyOTHER | 0 | Nov 12, 2024 | clinicaltrials |
| NCT03318900 | T-Cell Infusion, Aldesleukin, and Utomilumab in Treating Patients With Recurrent Ovarian Cancer | completed | Phase 1 / Phase 2 | 5 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 7, 2024 | clinicaltrials |
| NCT04493619 | PLX2853 as a Single Agent in Advanced Gynecological Malignancies and in Combination With Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer | terminated | Phase 1 / Phase 2 | 37 | Opna Bio LLCINDUSTRY | 2 | Nov 4, 2024 | clinicaltrials |
| NCT06650709 | NEoadjuvant Olaparib Combination OvArian Cancer Targeted Study(NEOCATS) | not yet recruiting | Phase 2 | 40 | British Columbia Cancer AgencyOTHER | 0 | Oct 23, 2024 | clinicaltrials |
| NCT03345485 | Study of the Safety, Pharmacokinetics and Efficacy of Tinostamustine in Patients With Advanced Solid Tumors.(EDO-S101) | completed | Phase 1 / Phase 2 | 71 | Mundipharma Research LimitedINDUSTRY | 5 | Oct 21, 2024 | clinicaltrials |
| NCT05012397 | Milademetan in Advanced/Metastatic Solid Tumors | terminated | Phase 2 | 40 | Rain Oncology IncINDUSTRY | 1 | Oct 17, 2024 | clinicaltrials |
| NCT05620134 | Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer | active not recruiting | Phase 1 / Phase 2 | 263 | Salubris Biotherapeutics IncINDUSTRY | 2 | Oct 15, 2024 | clinicaltrials |
| NCT04913337 | Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies | unknown | Phase 1 / Phase 2 | 179 | NGM Biopharmaceuticals, IncINDUSTRY | 3 | Oct 2, 2024 | clinicaltrials |
| NCT06620029 | BMX-001 + Paclitaxel in Adult Patients With Advanced, Recurrent, Metastatic Ovarian or Endometrial Cancer | not yet recruiting | Phase 1 / Phase 2 | 27 | BioMimetix JV, LLCINDUSTRY | 1 | Oct 1, 2024 | clinicaltrials |
| NCT03648489 | Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)(DICE) | completed | Phase 2 | 134 | Imperial College LondonOTHER | 2 | Sep 20, 2024 | clinicaltrials |
| NCT03493464 | BR55 in Characterization of Ovarian Lesions | terminated | Phase 2 | 14 | Bracco Diagnostics, IncINDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05700669 | Study to Assess Safety and Efficacy of AsiDNA in Combination with Olaparib in Participants with Recurrent Solid Tumors | completed | Phase 1 / Phase 2 | 3 | Valerio TherapeuticsINDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06600841 | Adebrelimab Combined with Non-platinum Chemotherapy and Fuzuloparib in Recurrent Platinum-resistant Ovarian Cancer | not yet recruiting | Phase 2 | 37 | Fujian Cancer HospitalOTHER_GOV | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06014190 | HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer | recruiting | Phase 2 | 460 | Hansoh BioMedical R&D CompanyINDUSTRY | 1 | Aug 29, 2024 | clinicaltrials |
| NCT06574763 | Neoadjuvant RC48 Plus Carboplatin for HER2-expressing Advanced Ovarian Cancer | unknown | Phase 2 | 47 | Sun Yat-sen UniversityOTHER | 0 | Aug 28, 2024 | clinicaltrials |
| NCT01696032 | SGI-110 in Combination With Carboplatin in Ovarian Cancer(SGI-110) | completed | Phase 2 | 120 | Astex Pharmaceuticals, Inc.INDUSTRY | 3 | Aug 27, 2024 | clinicaltrials |
| NCT05475184 | A Study to Evaluate the Efficacy and Safety of JPI-547 in Platinum-resistant, Advanced/Relapsed Ovarian Cancer Subjects Previously Treated With a PARP Inhibitor | unknown | Phase 2 | 58 | Onconic Therapeutics Inc.INDUSTRY | 1 | Aug 27, 2024 | clinicaltrials |
| NCT04248153 | Optimal Timing of BR55 CEUS of the Ovaries | terminated | Phase 2 | 3 | Bracco Diagnostics, IncINDUSTRY | 1 | Aug 23, 2024 | clinicaltrials |
| NCT00819169 | QUILT-3.026: AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors | terminated | Phase 1 / Phase 2 | 89 | NantCell, Inc.INDUSTRY | 0 | Aug 20, 2024 | clinicaltrials |
| NCT04377087 | Delayed Initiation of Olaparib Maintenance Therapy in Platinum Sensitive Recurrent Ovarian Cancer | terminated | Phase 2 | 3 | Sarah E TaylorOTHER | 1 | Aug 20, 2024 | clinicaltrials |
| NCT06552858 | Fluzoparib Combined With Dalpiciclib for Platinum Resistant Recurrent Ovarian Cancer | not yet recruiting | Phase 2 | 30 | Fudan UniversityOTHER | 1 | Aug 14, 2024 | clinicaltrials |
| NCT06065059 | Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors | terminated | Phase 1 / Phase 2 | 7 | Tango Therapeutics, Inc.INDUSTRY | 1 | Aug 13, 2024 | clinicaltrials |
| NCT06544460 | Secondary Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for PARP Inhibitors Resistance Patients | not yet recruiting | Phase 2 | 94 | Fudan UniversityOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT04787289 | A Comparison of 2 Standard Doses of Bevacizumab in Combination With Chemotherapy in Epithelial Ovarian Cancer | unknown | Phase 2 | 244 | British Columbia Cancer AgencyOTHER | 1 | Aug 7, 2024 | clinicaltrials |
| NCT05001282 | A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα) | terminated | Phase 1 / Phase 2 | 79 | Elucida OncologyINDUSTRY | 1 | Aug 7, 2024 | clinicaltrials |
| NCT03127098 | QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer | terminated | Phase 1 / Phase 2 | 3 | NantCell, Inc.INDUSTRY | 1 | Aug 6, 2024 | clinicaltrials |
| NCT06531486 | A Study of XS-02 Capsules in Patients With Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 96 | NovaOnco Therapeutics Co., Ltd.INDUSTRY | 0 | Aug 1, 2024 | clinicaltrials |
| NCT03323398 | Dose Escalation and Efficacy Study of mRNA-2416 for Intratumoral Injection Alone and in Combination With Durvalumab for Participants With Advanced Malignancies | terminated | Phase 1 / Phase 2 | 79 | ModernaTX, Inc.INDUSTRY | 1 | Jul 31, 2024 | clinicaltrials |
| NCT03602586 | Testing Whether the Combination of Two Immunotherapy Drugs Have Activity in Recurrent or Persistent Clear Cell Ovarian Cancer | completed | Phase 2 | 14 | National Cancer Institute (NCI)NIH | 2 | Jul 26, 2024 | clinicaltrials |
| NCT04408599 | A Safety and Tolerability Study of NC410 in Subjects With Advanced or Metastatic Solid Tumors | terminated | Phase 1 / Phase 2 | 46 | NextCure, Inc.INDUSTRY | 1 | Jul 25, 2024 | clinicaltrials |
| NCT05924776 | Plasmodium Immunotherapy for Advanced Ovarian Cancer | not yet recruiting | Phase 2 / Phase 3 | 30 | CAS Lamvac (Guangzhou) Biomedical Technology Co., Ltd.INDUSTRY | 1 | Jul 22, 2024 | clinicaltrials |
| NCT04570839 | COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors. | completed | Phase 1 / Phase 2 | 48 | Compugen LtdINDUSTRY | 1 | Jul 18, 2024 | clinicaltrials |
| NCT03759600 | Japan Phase 2 Study of Niraparib in Participants With Advanced, Relapsed Ovarian Cancer | completed | Phase 2 | 20 | TakedaINDUSTRY | 1 | Jul 16, 2024 | clinicaltrials |
| NCT03989336 | A Study of the Pan-immunotherapy in Patients With Relapsed/Refractory Ovarian Cancer | completed | Phase 2 | 84 | Chinese PLA General HospitalOTHER | 1 | Jul 15, 2024 | clinicaltrials |
| NCT04807166 | Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer | active not recruiting | Phase 2 | 56 | Wenjun ChengOTHER | 1 | Jul 3, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Dec 11, 2024source: clinicaltrials